CDC staff with their names on Kline patents - OUTRAGEOUS

[Guest guest]

Subject: CDC staff with their names on Kline

patents

Date: Thursday, March 16, 2006 12:06:51

http://v3.espacenet.com/textdoc?DB=EPODOC & IDX=AU4392093 & F=8

Compositions useful in diagnosis and prophylaxis of

lyme disease

Bibliographic data Description Claims

Mosaics Original document

INPADOC legal status

Patent number: AU4392093 Publication date:

1993-12-30

Inventor: GOLDE WILLIAM T; ROEHRIG JOHN T;

BURKOT THOMNAS; PIESMAN JOSEPH F; JOHNSON BARBARA J B;

MAYER LEONARD W; KEEN MARK G; HUNT ANN R

*** [CDC staff] ***

Applicant: SMITHKLINE BEECHAM CORP; US HEALTH

Classification:

- international: A61K39/02; C07K14/20;

C07K16/12; A61K38/00; A61K39/02;

C07K14/195; C07K16/12; A61K38/00; (IPC1-7): A61K39/00;

A61K39/02;

C07K3/00; C12Q1/00 - european: A61K39/02D;

C07K14/20; C07K16/12A10

Application number: AU19930043920D 19930526

Priority number(s): US19920889015 19920526;

US19920944464 19920914;

US19920992896 19921218

View INPADOC patent family

DESCRIPTION:

http://v3.espacenet.com/textdes?DB=EPODOC & IDX=AU4392093 & F=8 & QPN=AU439...

" Summary invention provides isolated B. burgdorferi

antigens which are regulated and differentiated by

growth of the B. burgdorferi in a tick vector. Novel

antigens of the invention are listed below in Table I.

Certain of these antigens are characterized as being

B. burgdorferi B31 strain specific and *** major

histocompatibility complex(MHC) nonrestricted. Certain

other of these antigens are characterized as being MHC

restricted. Sera generated to these antigens (B31 MHC

nonrestricted and B31 MHC restricted) are further

characterized by the ability or lack of ability to

react with B. burgdorferi JD-1 strain; the antigens

themselves (B31 MHC nonrestricted and B31 MHC

restricted) are further characterized by being

homologous or heterologous with B. burgdorferi JD-1

strain antigens. The most preferred antigens of

this invention, because of their ability to induce

cross-strain immunity to B. burgdorferi in different

animal haplotypes, are characterized by being B31 MHC

nonrestricted, JD-1 crossreactive, and JD-1

nonrestricted. Other antigens are also useful in

vaccine compositions and as diagnostics.*** "

- - - - -

That means ***CDC knows*** that there is a genetic

suscreptability to have the non-arthritis presentation

of Lyme, just as there is a genetic susceptibility to

having arthritis Lyme.

Strain B31 does not express much OspC, so CDC allowed

the major " primary immunodpminant antigens, " OspA, B,

and C to be left out of the bloodwork for Lyme if

anyone uses a lab which uses the B31 strain.

Which is QUEST LABS and Kline.

That means you lose the best 3 shots of having been

indentified as having Lyme disease.

Now you see that the CDC is complicit in this crime,

because they clearly know better, and there is a

*clear financial interest* for CDC staff to be

spinning Lyme. If anyone uses these patented antigens

in a recombinant form for either a test or vaccine,

they have to pay CDC staff royalties.

KMDickson

--

If you have an important point to make, don't try to

be subtle or clever. Use a pile driver. Hit the point

once. Then come back and hit it again. Then hit it a

third time-a tremendous whack. Winston Churchill

http://actionlyme.org